ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Maps Key Remlifansirin Readouts at JPM Conf [Yahoo! Finance]
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Acadia Pharmaceuticals Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at
Wall St
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $40.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.